Bayesian Capital Management, LP Viking Therapeutics, Inc. Transaction History
Bayesian Capital Management, LP
- $600 Million
- Q2 2025
A detailed history of Bayesian Capital Management, LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 16,200 shares of VKTX stock, worth $537,516. This represents 0.07% of its overall portfolio holdings.
Number of Shares
16,200Holding current value
$537,516% of portfolio
0.07%Shares
7 transactions
Others Institutions Holding VKTX
# of Institutions
451Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$337 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$200 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$125 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$108 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$104 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.54B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...